Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

David Cruz Hernandez, Marlen Metzner, Anne Pieta de Groot, Batchimeg Usukhbayar, Natalina Elliott, Irene Roberts, Paresh Vyas

Blood (2020) 136 (12): 1460–1465.

https://doi.org/10.1182/blood.2020005610

Published: 2020

Includes: Supplemental data

Journal Articles

Induction of a Leukemic Bone Marrow Niche Mediated By TGFB1 of Leukemic Blasts in Pediatric Acute Mekaryoblastic Leukemia: Results of an in Vitro and In Vivo Analysis

Theresa Hack, MSc, Stefanie Bertram, MD, Guntram Büsche, MD, Helmut Hanenberg, MD, Ludger Klein-Hitpass, PhD, Nils Von Neuhoff, PhD, Dirk Reinhardt, MD, Markus Schneider, PhD, Mareike Rasche, MD

Blood (2019) 134 (Supplement_1): 3734.

https://doi.org/10.1182/blood-2019-126536

Published: 2019

Journal Articles

Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group

Blood (2019) 134 (Supplement_1): 3848.

https://doi.org/10.1182/blood-2019-123302

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

Functional and Molecular Consequences of Trisomy 21 on Human Fetal Hematopoiesis

Elvin Wagenblast, PhD, Gabriela Krivdova, BSc, MSc, Olga I. Gan, PhD, Johann K. Hitzler, MD, John E. Dick, PhD, Eric R. Lechman, PhD

Blood (2018) 132 (Supplement 1): 1317.

https://doi.org/10.1182/blood-2018-99-119734

Published: 2018

Journal Articles

Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome

Jian Chen, PhD, Yue Li, MD MSC, Fouad Yousif, Sagi Abelson, PhD, Sanaz Manteghi, PhD, John D. McPherson, PhD, Johann K. Hitzler, MD

Blood (2018) 132 (Supplement 1): 442.

https://doi.org/10.1182/blood-2018-99-117198

Published: 2018

Journal Articles

The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS

R. Spencer Tong, BA, Wing Hing Wong, BSc, David R. O'Leary, Kathleen S. Jay, MS, RN, PNP-BC, D. Katherine Grange, MD, Jason Berman, MD, Johann K. Hitzler, MD, Todd E Druley, MD PhD

Blood (2018) 132 (Supplement 1): 3839.

https://doi.org/10.1182/blood-2018-99-120168

Published: 2018

Journal Articles

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Blood (2018) 132 (Supplement 1): 543.

https://doi.org/10.1182/blood-2018-99-116661

Published: 2018

Journal Articles

Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis

Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath, Gaetan Juban, PhD, Nathalie Sakakini, PhD, Kelly Soady, PhD, Hedia Chagraoui, PhD, Bilyana Stoilova, PhD, Catherine Garnett, Ludovic Lhermitte, MD, Elena Karkoulia, PhD, John Strouboulis, PhD, Catherine Porcher, PhD, Irene Roberts, MD

Blood (2017) 130 (Supplement 1): 3798.

https://doi.org/10.1182/blood.V130.Suppl_1.3798.3798

Published: 2017

Journal Articles

Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS

Irene Roberts, MD, Neha Bhatnagar, ND, Amelie Chaussade, MD, Laure Nizery, MD, Helen Richmond, RSCN, Natalina Elliott, PhD, Gemma Buck, BSc, Marlen Metzner, MSc, Alison Kennedy, MSc, Catherine Garnett, Kelly Perkins, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath

Blood (2017) 130 (Supplement 1): 569.

https://doi.org/10.1182/blood.V130.Suppl_1.569.569

Published: 2017

Journal Articles

Myeloid leukemia associated with Down syndrome

Caroline E. Talsma, Daniel F. Boyer

Blood (2017) 130 (2): 230.

https://doi.org/10.1182/blood-2017-02-768242

Published: 2017

Journal Articles

Looking up for AML in Down syndrome

Jessica C. Shand

Blood (2017) 129 (25): 3273–3274.

https://doi.org/10.1182/blood-2017-04-778977

Published: 2017

Journal Articles

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis

Blood (2017) 129 (25): 3304–3313.

https://doi.org/10.1182/blood-2017-01-764324

Published: 2017

Includes: Supplemental data

Journal Articles

Down syndrome and AML: where do we go from here?

Daisuke Tomizawa, E. Anders Kolb

Blood (2017) 129 (25): 3274–3275.

https://doi.org/10.1182/blood-2017-04-780031

Published: 2017

Journal Articles

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

Madita Uffmann, Mareike Rasche, Martin Zimmermann, Christine von Neuhoff, Ursula Creutzig, Michael Dworzak, Lenie Scheffers, Henrik Hasle, C. Michel Zwaan, Dirk Reinhardt, Jan-Henning Klusmann

Blood (2017) 129 (25): 3314–3321.

https://doi.org/10.1182/blood-2017-01-765057

Published: 2017

Includes: Supplemental data

Journal Articles

Adolescents and Young Adults with Acute Myeloid Leukemia Are Associated with Higher Treatment-Related Mortality and Inferior Overall Survival after Allogeneic Hematopoietic Cell Transplantation Compared with Children

Daisuke Tomizawa, MD, PhD, Shiro Tanaka, PhD, Tadakazu Kondo, MD PhD, Yoshiko Hashii, MD PhD, Yasuyuki Arai, MD PhD, Kazuko Kudo, MD PhD, Takashi Taga, MD PhD, Jiro Inagaki, MD, Katsuyoshi Koh, MD, Masami Inoue, MD, Junji Tanaka, MD PhD, Koji Kato, MD PhD, Yoshiko Atsuta, MD PhD, Souichi Adachi, MD, PhD, HIroyuki Ishida, MD

Blood (2016) 128 (22): 4702.

https://doi.org/10.1182/blood.V128.22.4702.4702

Published: 2016

Journal Articles

MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome

Lital Shaham, Elena Vendramini, Yubin Ge, Yaron Goren, Yehudit Birger, Marloes R. Tijssen, Maureen McNulty, Ifat Geron, Omer Schwartzman, Liat Goldberg, Stella T. Chou, Holly Pitman, Mitchell J. Weiss, Shulamit Michaeli, Benjamin Sredni, Berthold Göttgens, John D. Crispino, Jeffrey W. Taub, Shai Izraeli

Blood (2015) 125 (8): 1292–1301.

https://doi.org/10.1182/blood-2014-06-581892

Published: 2015

Includes: Supplemental data

Journal Articles

Clinical and Hematologic Impact of Fetal and Perinatal Variables on Mutant GATA1 Clone Size in Neonates with Down Syndrome

Neha Bhatnagar, MBChB MRCPCH FRCPath, Kelly Perkins, Sarah Filippi, Helen Richmond, RN, Joanna Bonnici, Kate Alford, Georgina Hall, BSc, PhD MBBS, FRCP, FRCPath, Gaëtan Juban, PhD, Simon McGowan, Anindita Roy, MDPhD, Natalina Elliott, Michael Stumpf, Alice Norton, MB, Paresh Vyas, MDPhD, Irene Roberts, MDFRCP FRCPCH FRCPath

Blood (2014) 124 (21): 2349.

https://doi.org/10.1182/blood.V124.21.2349.2349

Published: 2014

Journal Articles

Risk-Oriented Therapy for Myeloid Leukemia of Down Syndrome: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG)

Blood (2014) 124 (21): 3668.

https://doi.org/10.1182/blood.V124.21.3668.3668

Published: 2014

Journal Articles

GATA1 -mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia

Blood (2013) 122 (24): 3908–3917.

https://doi.org/10.1182/blood-2013-07-515148

Published: 2013

Includes: Supplemental data

NARROW

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

Induction of a Leukemic Bone Marrow Niche Mediated By TGFB1 of Leukemic Blasts in Pediatric Acute Mekaryoblastic Leukemia: Results of an in Vitro and In Vivo Analysis

Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Functional and Molecular Consequences of Trisomy 21 on Human Fetal Hematopoiesis

Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome

The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis

Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS

Myeloid leukemia associated with Down syndrome

Looking up for AML in Down syndrome

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Down syndrome and AML: where do we go from here?

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

Adolescents and Young Adults with Acute Myeloid Leukemia Are Associated with Higher Treatment-Related Mortality and Inferior Overall Survival after Allogeneic Hematopoietic Cell Transplantation Compared with Children

MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome

Clinical and Hematologic Impact of Fetal and Perinatal Variables on Mutant GATA1 Clone Size in Neonates with Down Syndrome

Risk-Oriented Therapy for Myeloid Leukemia of Down Syndrome: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG)

GATA1 -mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only